Schnell, Alexandra http://orcid.org/0000-0003-3442-7750
Littman, Dan R.
Kuchroo, Vijay K. http://orcid.org/0000-0001-7177-2110
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Research Resources (R01NS045937, R01NS30843, R01AI144166, P01AI073748, P01AI039671, P01AI056299, R01AI158687, RO1CA255635)
Article History
Received: 22 July 2022
Accepted: 4 November 2022
First Online: 3 January 2023
Competing interests
: V.K.K. is cofounder of Celsius Therapeutics, Tizona Therapeutics, Larkspur Biosciences and Bicara Therapeutics. His interests are reviewed and managed by the Brigham and Women’s Hospital and Partners Health Care in accordance with their conflict of interest policies. D.R.L. is cofounder of Vedanta Biosciences and Immunai, on the advisory boards of ChemoCentryx and IMIDomics and on the board of directors of Pfizer. The other authors declare no competing interests.